CN102245184A - 用于治疗癌症的恩扎妥林 - Google Patents

用于治疗癌症的恩扎妥林 Download PDF

Info

Publication number
CN102245184A
CN102245184A CN2009801503024A CN200980150302A CN102245184A CN 102245184 A CN102245184 A CN 102245184A CN 2009801503024 A CN2009801503024 A CN 2009801503024A CN 200980150302 A CN200980150302 A CN 200980150302A CN 102245184 A CN102245184 A CN 102245184A
Authority
CN
China
Prior art keywords
patient
cancer
hdac2
grace
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801503024A
Other languages
English (en)
Chinese (zh)
Inventor
G·甘吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102245184A publication Critical patent/CN102245184A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2009801503024A 2008-12-15 2009-12-07 用于治疗癌症的恩扎妥林 Pending CN102245184A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
US61/122,451 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN102245184A true CN102245184A (zh) 2011-11-16

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801503024A Pending CN102245184A (zh) 2008-12-15 2009-12-07 用于治疗癌症的恩扎妥林

Country Status (11)

Country Link
US (1) US20110288032A1 (https=)
EP (1) EP2376081A2 (https=)
JP (1) JP2012512157A (https=)
KR (1) KR20110084533A (https=)
CN (1) CN102245184A (https=)
AU (1) AU2009330492A1 (https=)
BR (1) BRPI0922367A2 (https=)
CA (1) CA2746085A1 (https=)
EA (1) EA201170821A1 (https=)
MX (1) MX2011006433A (https=)
WO (1) WO2010074936A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CA2862320A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal cancer
JP6215235B2 (ja) * 2012-01-24 2017-10-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌の治療方法
SG11201404888SA (en) * 2012-02-17 2014-09-26 Pharmacyclics Inc Combinations of histone deacetylase inhibitor and pazopanib and uses thereof
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
MX372671B (es) * 2013-07-19 2020-04-23 Onyx Therapeutics Inc Inhibidores de proteasoma de epoxicetona peptídica en combinacion con inhibidores de cinasa pim para el tratamiento de canceres.
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
WO2006135733A2 (en) * 2005-06-10 2006-12-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Modulation of peripheral clocks in adipose tissue

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019851A1 (en) * 2004-07-23 2006-02-23 Eli Lilly And Company Methods for diagnosing and treating diabetic microvascular complications
WO2006135733A2 (en) * 2005-06-10 2006-12-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Modulation of peripheral clocks in adipose tissue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L NOLAN ET AL: "Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?", 《BRITISH JOURNAL OF CANCER》 *

Also Published As

Publication number Publication date
JP2012512157A (ja) 2012-05-31
WO2010074936A2 (en) 2010-07-01
KR20110084533A (ko) 2011-07-25
EA201170821A1 (ru) 2011-12-30
AU2009330492A1 (en) 2010-07-01
BRPI0922367A2 (pt) 2016-05-24
US20110288032A1 (en) 2011-11-24
WO2010074936A3 (en) 2010-09-16
EP2376081A2 (en) 2011-10-19
CA2746085A1 (en) 2010-07-01
MX2011006433A (es) 2011-07-19

Similar Documents

Publication Publication Date Title
Pillai et al. Causes, consequences, and therapy of tumors acidosis
CN102245184A (zh) 用于治疗癌症的恩扎妥林
Ilson et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
KR102511024B1 (ko) 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
Cheng et al. E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness
Khammanivong et al. A novel MCT1 and MCT4 dual inhibitor reduces mitochondrial metabolism and inhibits tumour growth of feline oral squamous cell carcinoma
Del Mare et al. Diffusing alpha-emitters radiation therapy promotes a proimmunogenic tumor microenvironment and synergizes with programmed cell death protein 1 blockade
Wu et al. Cutaneous T-cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Kα/δ and HDAC
Ki et al. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors
Patki et al. In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells
US20250255871A1 (en) Systems and methods for treating cancer
WO2016148969A1 (en) Kub5/hera as a determinant of sensitivity to dna damage
EP4139484B1 (en) Therapeutic methods for preventing tumor metastasis and tumor recurrence
US20230285339A1 (en) Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitors
Skorupski et al. Phase I/II clinical trial of 2‐difluoromethyl‐ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma
US8853274B1 (en) Compositions and methods for targeting glioblastomas cells
US20250049823A1 (en) Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
Xia et al. PS980 Grik5 drives self renewal pathways in human acute myeloid leukemia cells
Mureddu et al. P10. 20. A RADIOMICS-BASED GRADING OF PAEDIATRIC GLIOMAS USING [18F] F-DOPA PET/CT: INSIGHTS FROM THE PERITUMORAL BORDER
양시은 Role of AK1 in Metabolic Reprogramming and Metastatic Regulation of Triple-Negative Breast Cancer
Zhu et al. MiR-29a/DNMT3A axis participates in Dihydroartemisinin's suppression on lung adenocarcinoma: Implications for overcoming acquired resistance to EGFR-TKIs
van Dijk A proteomic approach for leukemia epigenetics research: target identification, prognostication and therapeutic guidance
Shi et al. NR1I3 inhibits colorectal cancer growth by enhancing PCK1-mediated gluconeogenesis
Gupta et al. PATH-89. The single cell landscape of NF1-associated gliomas pre-and post-treatment and comparison to their sporadic counterparts
US20130209460A1 (en) Methods and kits used in identifying glioblastoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20111116